INTRODUCTION
MicroRNAs (miRNAs) are a class of small regulatory RNAs of $22 nt involved in diverse biological pathways as key post-transcriptional regulators of gene expression. 1 These miRNAs pair with complementary sites of the mRNAs and mediate post-transcriptional repression, also termed RNAi. 2, 3 RNAi-mediated gene silencing has been extensively studied in the laboratory and may provide a powerful therapeutic approach to human diseases to selectively modulate gene expression because of its high efficiency and sequence specificity. 4, 5 Short hairpin RNAs (shRNAs) are a class of RNA polymerase (pol) III-driven shRNAs that mimic the structure of miRNA precursor intermediates. 6 shRNAs are expressed in mammalian cells to achieve efficient knockdown; however, it has been previously reported that oversaturation of processing machinery in cells expressing shRNAs from heterologous promoters at high levels is associated with cytotoxic effects [7] [8] [9] [10] [11] and increased mortality in mice in transgenic model systems. 12, 13 For clinical application of RNAi therapeutics, alternative expression systems, including both more physiologic levels of expression and the capacity to effect lineage-specific expression, may be required. This can be accomplished by embedding shRNAs into flanking miRNA scaffolds, termed miRNA-adapted shRNAs (shRNA miR s), which mimic the structure of endogenous miRNAs as described previously by us and others. 14, 15 We have recently reported a clinically applicable pol II promoter-driven viral shRNA miR vector for knocking down BCL11A with improved efficiency and less cytotoxicity. 14, 15 BCL11A interacts with other transcription factors to repress the g-globin (fetal) gene during adult life leading to increased b-globin (adult) gene expression. 16, 17 The molecular switch from fetal to adult globin is associated with emergence of signs and symptoms of sickle cell disease (SCD) and b-thalassemias in individuals with b-globin mutations. 16, 18 One therapeutic approach to treatment of b-hemoglobinopathies is the knockdown of BCL11A, which simultaneously restores g-globin gene expression and reduces mutant b-globin expression (NCT03282656).
Endogenous miRNAs are transcribed as primary transcripts (pri-miRNA), which are cleaved by the microprocessor complex, DROSHA-DGCR8. 19 DGCR8 binds to the hairpin and directs
RNase III-like endonuclease DROSHA to the intended cleavage site. [20] [21] [22] Alternatively, DROSHA itself can also bind to the primiRNA and perform endonucleolytic cleavage. 23 Subsequently, the pre-miRNA is exported from the nucleus to the cytoplasm by Exportin-5 and further processed by Dicer. 24 The resulting small interfering RNA (siRNA) duplex binds to the Argonaute (Argo-) protein subunit of the RNA-induced silencing complex (RISC), where strand selection and target mRNA cleavage occur. 25 We observed that the viral titers of hairpin shRNA miR vectors were consistently lower than non-hairpin-containing vectors. We hypothesized that low recombinant viral titers were due to cleavage of viral genomic RNA by the endogenous microprocessor complex during virus assembly in vector packaging cells. To test this hypothesis, we generated knockout (KO) of DROSHA, the core catalytic component of the microprocessor complex, in viral vector packaging cells by deleting exons 4-30 using CRISPR/Cas9. 26 The DROSHA KO cell lines were tested for generation of hairpin shRNA miR recombinant virus. We demonstrate a recovery of viral titer and show correlation of the absence of shRNA miR processing, and an increase in the amount of full-length vector genomic RNA in both producer cells and viral particles. These insights are important for the clinical development of any hairpin-containing viral vectors that induce RNAi to treat diseases.
RESULTS

DROSHA KO Strategy Using CRISPR/Cas9
To determine the influence of miRNA processing on the lower titers observed in shRNA-containing vectors, we targeted the DROSHA-DGCR8 microprocessor complex for deletion. We utilized a CRISPR/Cas9 vector, pX458, for the co-expression of single guide RNAs (sgRNAs), SpCas9, and a GFP reporter ( Figure 1A ). 26 The DROSHA gene is located on chromosome 5, spans 132 kb, and consists of 35 exons with the start codon in exon 3 ( Figure 1B) . 23 We selected two sgRNAs targeting the 5 0 end of exon 4 (labeled gRNAs 1-2) of DROSHA and two guide RNAs (gRNAs) targeting the 3 0 end of exon 30 (labeled gRNAs 3-4) (Table S1 ) to affect a deletion of nearly the entire coding region.
We co-transfected combinations of 5 0 and 3 0 targeting gRNAs into HEK293T/17 cells and sorted GFP high-expressing cells. Sorted cells were plated at low density, and resulting colonies were picked individually to establish clonal cell lines. The clones were screened by polymerase chain reaction (PCR) analysis to identify a complete DROSHA (D) KO cell line using DROSHA-specific primers ( Figure 1C Figure 1C , lower panel at arrowheads). As seen in WT, heterozygous KO, and homozygous KO, the PCR product of 402 bp is absent in lane 3 (primers 1 and 3), indicating that complete deletion of the targeted fragment did not occur. We next confirmed the complete loss of DROSHA protein by immunoblot analysis ( Figure 1D ). For WT, the expected DROSHA protein band was observed at 170 kDa in lane 1. For homozygous deletion, the absence of DROSHA protein is confirmed in lane 3. In case of the heterozygous KO, the re-arrangement of one allele leads to an $50% reduction in band intensity (lane 2). We next determined the effect of reduced DROSHA expression on cell growth ( Figure 1E ). Complete absence of DROSHA protein was associated with significantly lower proliferation compared with either WT or the single-allele rearranged clone.
Characterization of DROSHA KO Cell Lines
We next determined the effect of DROSHA KO on the capacity of cells to cleave an RNA hairpin embedded in a lentivirus vector. We constructed a control non-hairpin-containing plasmid (LeGO-SFFV) by removing the BCL11A shRNA miR hairpin from the LeGO-SFFVshRNA miR 5 plasmid (Figure 2A ). 14 In LeGO-SFFV-shRNA miR 5, the shRNA is embedded in an miRNA223 scaffold (shRNA miR ) to allow expression from pol II promoters in mammalian cells. Plasmids were transfected into WT or homozygous KO cells, and northern blot was performed using a labeled RNA probe to determine the presence or absence of a processed small RNA derived from shRNA miR 5 (Figure 2B) . In WT cells transfected with the hairpin-containing plasmid In order to determine the effect of miRNA processing on the generation of full-length viral genomic RNA during virus production, we performed northern blot analysis targeting the stem region of the hairpin on cell lysates of 293T packaging cell lines transfected with the plasmids shown in Figure 2A . The intensity of ribosomal 28S and 18S RNAs was used to ensure equal RNA loading in each lane of the northern blot ( Figure 3A) . In WT cells, we observed a relative decrease in the viral genomic length RNA transcript band intensity (at arrowhead) for the hairpin shRNA miR -containing (LeGO- In order to determine whether the change in full-length mRNA expression was associated with an increase in full-length viral genomic RNA transcript in packaged virions, we performed northern blot analysis on virus particles generated from 293T packaging cell lines. Similar to findings in packaging cell line lysates, we observed a decrease in the viral genomic RNA transcript band intensity in virus particles harvested from WT producer cells for the hairpin shRNAmiR-containing (LeGO-SFFV-shRNAmiR5) compared with non-hairpin-containing (LeGO-SFFV) virus ( Figure 4A ). In contrast, we saw no apparent reduction in viral genomic RNA transcript band intensities for the hairpin shRNAmiR-containing (LeGO-SFFVshRNAmiR5) compared with non-hairpin-containing (LeGO-SFFV) virus. Densitometric quantitation from the northern blot analysis of the full-length genomic RNA confirmed an $40%-50% reduction of full-length genomic RNA in viral particles containing the hairpin from WT cells with a ratio of $0.9 in viral particles from the homozygous KO cell line ( Figure 4B ).
DROSHA KO Leads to an Increase in the Viral Titer for Hairpin Vectors
To determine the effect of the lack of DROSHA activity on recombinant virus production, we next compared the titer of supernatant harvested from populations of transfected 293T packaging cells on murine erythroleukemia (MEL) cells. We compared the titers produced in heterozygous KO and homozygous KO producer cells versus WT cells as a ratio of the titer of hairpin-to no-hairpin-containing vectors ( Figure 5A ). In WT cells, we confirmed an $40% decrease in the relative viral titer of hairpin compared with nonhairpin-containing vectors. In producer cells deficient in DROSHA, no decrease in the viral titer was seen, with the viral titer ratio close to 1. There appeared to be a dosage dependency on DROSHA protein expressed in the cell, because producer cells with one allele disruption and $50% DROSHA protein showed an intermediate decrease in viral titer and viral titer ratio between 0.7 and 0.8.
Because the vector-encoded mRNA contains the Venus fluorescent reporter and the shRNA miR hairpin in a monocistronic mRNA, DROSHA-mediated excision of the hairpin leads to cleavage and subsequent degradation of the mRNA. Efficient cleavage of the mRNA should therefore be associated with reduced Venus expression. We examined the mean fluorescence intensity (MFI) of Venus in WT and Drosha KO 293T cells after transduction with the two vectors. Similar to the viral titer ratio in Figure 5A , we observed an $40% decrease in the expression as quantified by the MFI ratio of hairpinto non-hairpin-transduced cells ( Figure 5B ). In contrast, in homozygous KO cells, we observed no decrease in the MFI ratio of integrated vectors. Cells with one functional DROSHA allele showed an intermediate phenotype with an MFI ratio between 0.7 and 0.8.
Rescued DROSHA Activity Is Associated with Restoration of Viral Titers in Packaging Cell Lines
Next, we performed a rescue experiment using a WT cDNA and a transdominant (TN) mutant of DROSHA. The latter contains two point mutations at E1045Q and E1222Q, which causes loss of catalytic activity of DROSHA ( Figure 6A ). 27 We tested the effect of re-expression of DROSHA in homozygous KO cells on the resulting titers on MEL cells. First, we confirmed the expression of DROSHA by immunoblot analysis. As seen in Figure 6B , both the WT DROSHA and the TN mutant protein are expressed in homozygous 
DISCUSSION
Viral vector-based RNAi gene therapy is a powerful approach to modulate clinically important genes. In this study, we show that reduction in viral titers generated in packaging cell lines of shRNAmiR -containing vectors is directly related to the cleavage of the full-length viral genomic transcripts by DROSHA. We used CRISPR technology to generate DROSHA KO in 293T packaging cells. In the absence of DROSHA, shRNA miR hairpin-containing viral genomic RNAs were not cleaved. This lack of viral genomic RNA processing in packaging cells was associated with restoration of viral titer comparable with non-hairpin-containing vector constructs. Additionally, there was no difference between the expression of the hairpin vector versus non-hairpin-containing vector in infected DROSHA KO cells, suggesting that DROSHA also does not cleave shRNA miR hairpincontaining mRNA transcribed from the internal promoter of the integrated provirus. Finally, re-expression of WT DROSHA in homozygous KO cells led to a reduction in titer of hairpin-containing vectors. The difference in titer reduction in cells expressing the inactive mutant TN DROSHA versus WT DROSHA cDNAs strongly suggests that catalytic activity of DROSHA is important for the cleavage of shRNA miR hairpin-containing viral genomic RNA.
These studies extend published work suggesting an important role for the microprocessor complex in disrupting packaging of shRNA-containing viral vectors. Previously, it was reported that the presence of shRNA miR hairpin cassettes can negatively affect lentiviral vector titers, and inhibition of the RNAi pathway via saturation could rescue vector production. 24 In these studies, replacement of the cytomegalovirus promoter with an inducible promoter also resulted in restoration of the vector titer. In addition, it has been reported that inhibition of RNase III enzyme activity of DROSHA can increase titers of miRNA-encoding retroviruses. 28 Inhibition of DROSHA in the packaging cells resulted in impaired processing of mature miRNA from full-length retroviral transcripts, which led to more packaging of full-length viral transcripts into infectious virus particles. However, previous studies showed no direct proof of the cleavage of viral transcripts as a result of DROSHA activity and in association with the reduction in viral titers. Here, we report the generation of a packaging cell line that obviates that need for these manipulations and is the basis for an effective virus vector production system for all hairpincontaining constructs (Figure 7 ).
In summary, our data demonstrate the requirement of homozygous KO in producer cells for the efficient production of shRNA miR hairpin viruses. Our findings have important implications for future production of viral shRNA miR -containing vectors for RNAi-based therapy.
MATERIALS AND METHODS
Cloning of DROSHA Targeting CRISPR/Cas9 Plasmid DROSHA targeting sgRNAs were designed using online CRISPR design tools developed by Feng Zhang and colleagues (http://crispr. mit.edu/) 26 and CHOPCHOP (http://chopchop.cbu.uib.no/). 29, 30 Two gRNAs targeting the 5 0 end of exon 4 (labeled gRNAs 1-2) of DROSHA and two gRNAs targeting the 3 0 end of exon 30 (labeled gRNAs 3-4) were subsequently utilized (Table S1 ). The guide strand oligo sequences were synthesized from Invitrogen Custom DNA Oligos (Thermo Fisher Scientific, Waltham, MA, USA), annealed, and inserted into BbSI sites of S. pyogenes Cas9 cloning vector with 2A-EGFP (pX458; Addgene plasmid ID: 48139) ( Figure 6A ). The GenBank file for the plasmid is available through Addgene. 
Cell Culture
HEK293T/17 (ATCC CRL-11268) and MEL cells were maintained in DMEM or RPMI medium (Cellgro, Washington, DC, USA) supplemented with 10% fetal calf serum and 2% penicillin-streptomycin, respectively.
Generation of DROSHA KO Cell Lines
HEK293T/17 (ATCC CRL-11268) cells were transfected with CRISPR/Cas9 plasmids targeting DROSHA. We co-transfected 5 0 and 3 0 targeting gRNAs with 1 mg/mL linear polyethylenimine (PEI) (Polysciences, Warrington, PA, USA) and fluorescence-activated cell sorting (FACS) sorted for cells expressing high levels of GFP. Sorted cells were plated at low density, and individual clones were picked and expanded. The clones were screened by PCR analysis to identify DROSHA KO cell lines using a set of DROSHA primers (Table S2 ) and additionally analyzed for DROSHA expression by immunoblot analysis.
Immunoblot Analysis
DROSHA KO cell lines were lysed in radioimmunoprecipitation assay (RIPA) lysis buffer (Thermo Scientific, Rockford, IL, USA), with protease inhibitor (Roche, Mannheim, Germany). Samples were mixed suspended in 2Â Laemmli sample buffer supplemented with beta-mercaptoethanol. The mixtures were denatured by boiling and loaded onto a 10% SDS-polyacrylamide gel. Electrophoresis was performed to separate each sample according to size and subsequently transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA). Following blocking in PBS with 0.1% Tween 20 and 5% nonfat dry milk, the polyvinylidene fluoride membrane was incubated 
Proliferation of DROSHA KO Cell Lines
For initial seeding of cells, the cell number was calculated using a hemocytometer and trypan blue dye to distinguish viable from dead cells. Proliferation of cells was assessed using the fluorescence-based CyQUANT Cell Proliferation Assay (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. 1,000 cells/well were plated in a 96-well plate, and fluorescence measurements were made using a microplate reader with excitation at 485 nm and emission detection at 530 nm.
Construction of SFFV-BCL11A shRNA miR Plasmids
A control non-hairpin-containing (LeGO-SFFV) lentiviral vector plasmid was constructed by removing the BCL11A shRNA miR hairpin from the LeGO-SFFV-shRNA miR 5 plasmid 14 ( Figure 2A) . In LeGO-SFFV-shRNA miR 5, the shRNA is embedded in an hsamiRNA223 (shRNA miR ) backbone to allow expression from pol II promoters in mammalian cells. For northern blot analysis, total RNA was extracted from DROSHA KO cell lines 48 hr after transfection with lentiviral packaging plasmids. For the detection of viral genomic RNA in viral particles, virus supernatants were treated with Benzonase (Sigma-Aldrich, Saint Louis, MO, USA) to remove free RNA and DNA, followed by centrifugation at 13,000 Â g at 4 C overnight. Total RNA was extracted from viral pellets by concentrating the Benzonase-treated virus supernatant in a Beckmann XL-90 centrifuge using SW-28 swinging buckets. The total RNA was isolated using TRIzol reagent (Ambion, Austin, TX, USA), then resolved on a 15% polyacrylamide Trisborate-EDTA (TBE) urea gel or formaldehyde/agarose gel for separation of small RNAs or viral genomic RNA, respectively. RNA was transferred to Hybond-N+ nylon membrane (Amersham, Piscataway, NJ, USA) and UV-crosslinked. The blots were prehybridized using PerfectHyb Plus Hybridization buffer (Sigma, St. Louis, MO, USA) at 42 C for 1 hr. The blot was probe-labeled with either g-32P-labeled ATP (Perkin Elmer) and hybridized at 42 C overnight, or with a-32P-labeled dCTP (Perkin Elmer) at 58 C overnight. Blots were washed in 2Â sodium citrate, 0.1% SDS at room temperature, and exposed to film. Forward and reverse sequences for REV-responsive element (RRE) probe were as follows: 5 0 -GCTTTGTTCCTT GGGTTCTTG-3 0 and 5 0 -CCAGGAGCTGTTGATCCTTTAG-3 0 .
Statistical Analysis
All values are presented as the mean ± SD. Statistical significance was assessed by Student's t test. p < 0.05 was considered statistically significant.
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